Plain-English translation of NCT07172971 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a medication called dapagliflozin (a sodium-glucose cotransporter-2 inhibitor) to see if it can slow or prevent heart damage in young people with Duchenne muscular dystrophy. Duchenne affects the heart in most patients, and while current treatments help, they don't fully stop the progression—especially the development of scar tissue in the heart muscle. Researchers believe this medication could work differently than current heart treatments and might protect the heart before irreversible damage develops.
As treatments for Duchenne have improved, more patients are surviving longer but facing serious heart complications as the leading cause of death. This medication has shown promise in helping adult hearts, but it's never been tested in young people with Duchenne to see if it could prevent the heart scarring that happens over time.
You likely qualify if…
You likely don't qualify if…
You would take a daily tablet of the medication at home—the dose depends on your body weight. You would visit the research center for heart imaging (MRI), blood work, and checkups to see how the medication is working. The study starts with a small group to find the right safe dose, then expands to other participants. The research team will carefully monitor how your body handles the medication and how your heart responds over time.
AI-generated summary from trial data · Aug 22, 2026 · Not medical advice
United States